MERIT Acquires OSOD to Expand Ophthalmic Preclinical Capabilities

Advancing Sight Network and Miracles In Sight Merge to Form Precision Ocular Network

January 27, 2026

Healthcare Services

Advancing Sight Network and Miracles In Sight have merged and will operate under the new name Precision Ocular Network, combining their eye-banking, transplantation, and ocular research capabilities. The nonprofit merger aims to expand research into cellular therapeutics and retinal/other vision-loss treatments while improving collaboration and tissue distribution for clinicians and researchers.

Oragenics Acquires Odyssey Health Neurological Drug Assets

January 2, 2024

Pharmaceuticals

Oragenics, Inc. completed the acquisition of Odyssey Health, Inc.'s neurological drug therapy assets, including ONP-002, ONP-001 rights, a proprietary intranasal delivery device and related formulations. Odyssey retained its remaining assets and operations; Michael Redmond (former Odyssey CEO) was named President of Oragenics to oversee integration and advancement of the neurology pipeline as Oragenics prepares for Phase 2 studies of ONP-002.

Emmes Acquires Clinical Edge

September 28, 2022

Healthcare Services

Emmes, a global full-service clinical research organization, has acquired Clinical Edge, a Milwaukee-based provider of visual function examiner training and certification for ophthalmic clinical trials. The deal combines Clinical Edge with Emmes' Optym ophthalmology unit (rebranded OptymEdge), expanding Emmes' ophthalmology certification capabilities and geographic reach across the U.S., Europe and Asia.

Cadence Design Systems Acquires OpenEye Scientific

July 25, 2022

Software

Cadence Design Systems announced the acquisition of OpenEye Scientific Software for approximately $500 million, extending Cadence's computational software expertise into molecular modeling and simulation for life sciences. OpenEye's cloud-native Orion SaaS platform and scientific toolkits—used by 19 of the top 20 global pharmaceutical companies—will be combined with Cadence's algorithmic, solver and large-data management capabilities to accelerate computational drug discovery; the deal is expected to contribute about $40 million in fiscal 2023.

Sitero Acquires studyOS

November 5, 2025

Healthcare Services

Sitero has acquired the AI assets and business of studyOS, integrating studyOS’s Ash AI Clinical Trial Agent into its Mentor eClinical suite and launching SiteroAI to create an AI-powered CRO. studyOS’s technical and AI engineering teams will join Sitero and Ellis Butterfield, former CEO of studyOS, is appointed CTO to lead integration and product strategy. The combined platform aims to deliver measurable 20–30% efficiency gains across the clinical development lifecycle beginning in 2026.

Velocity Clinical Research Acquires Meridian Clinical Research

December 15, 2022

Healthcare Services

Velocity Clinical Research, a GHO-backed integrated research site organization, has acquired Meridian Clinical Research for an undisclosed amount. The deal creates the largest dedicated clinical research site organization globally (about 80 sites), expands Velocity's U.S. footprint to 25 states and adds Meridian's network of 35+ sites and experienced investigators and staff.